Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease

Inclusion Criteria: * The patient must be male or female over the age of 18. * The subject must have idiopathic Parkinson's disease. * The subject has Stage III by Hoehn and Yahr in the "on" state on a screening visit * Subjects suffering from anxiety, depression, cognitive dysfunction * Dopaminergic drugs should be taken in a stable dosage for 28 days prior to registration, and throughout the study * Patients who have signed an approved consent form and are consistent with both the clinical trial plan and follow-up. Exclusion Criteria: * Patients have atypical parkinsonism (eg, neuroleptics, metoclopramide, flunarizin), metabolic neurodegenerative disorders (eg, Wilson's disease), encephalitis, cerebrovascular disease or degenerative disease (e.g. progressive supranuclear palsy) * Patients who received deep brain stimulation * Patients with cancer, HIV, kidney or liver disease. * Patients taking new antipsychotic, antidepressant, anxiolytic or narcotic drugs for less than 3 months